Stock Events

Stock Events

Cyclacel Pharmaceuticals 

$0.96
91
-$0.01-0.95% Tuesday 20:24

Statistics

Day High
0.99
Day Low
0.95
52W High
33
52W Low
0.9
Volume
102,156
Avg. Volume
-
Mkt Cap
0
P/E Ratio
0
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
May 25
$2.4
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

12AugExpected
Q2 2025
Q3 2025
Q1 2026
Next
-72
-48.01
-24.03
-0.04
Expected EPS
N/A
Actual EPS
N/A

Financials

-26,074.42%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
43,000Revenue
-11.21MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CYCC. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap160.88B
Gilead Sciences is a biopharmaceutical company that competes in the development of drugs in areas such as oncology, where Cyclacel also operates.
AMGEN
AMGN
Mkt Cap176.21B
Amgen is a biotech firm focusing on human therapeutics, including treatments for cancer, which puts it in direct competition with Cyclacel's oncology focus.
Bristol-Myers Squibb
BMY
Mkt Cap116.4B
Bristol-Myers Squibb is involved in discovering, developing, and delivering innovative medicines, including cancer treatments that compete with Cyclacel's product pipeline.
Pfizer
PFE
Mkt Cap144.37B
Pfizer is a global pharmaceutical corporation with a broad portfolio, including oncology, directly competing with Cyclacel's cancer-focused therapies.
Merck
MRK
Mkt Cap275.09B
Merck is known for its high-quality research and development in pharmaceuticals, including cancer drugs, making it a competitor to Cyclacel.
Novartis
NVS
Mkt Cap282.55B
Novartis is a healthcare company that focuses on innovative medicines, with a strong emphasis on oncology, competing with Cyclacel in the cancer treatment market.
Abbvie
ABBV
Mkt Cap371.72B
AbbVie operates in the discovery of new medicines, including for cancer, directly competing with Cyclacel's research and development in oncology.
Astrazeneca
AZN
Mkt Cap281.6B
AstraZeneca is a global, science-led biopharmaceutical business that focuses on the discovery, development, and commercialization of prescription medicines, including in oncology, competing with Cyclacel.
Roche
RHHBY
Mkt Cap329.03B
Roche Holding AG is a pioneer in healthcare, with a strong focus on pharmaceuticals and diagnostics in oncology, making it a competitor to Cyclacel.
Johnson & Johnson
JNJ
Mkt Cap545.74B
Johnson & Johnson is a diverse healthcare company that has a pharmaceutical segment involved in the development of oncology treatments, competing with Cyclacel.

About

A diversified company operating in both the fire protection and biopharmaceutical industries. It expanded its portfolio by acquiring Fitters Sdn. Bhd., a Malaysian fire protection products and services group. Focuses on advancing opportunities in biopharmaceutical research and fire safety solutions to create sustainable long-term shareholder value.
Show more...
CEO
Dr. Sing Ee Wong
Employees
12
Country
United States
ISIN
US23254L8761

Listings

STU
DE
UXI0.STU
XNAS
US
BGMS
MU
DE
UXI0.MU
OTC Link
US
BGMSP

0 Comments

Share your thoughts

FAQ

What is Cyclacel Pharmaceuticals stock price today?▼
The current price of CYCC is $0.96 USD — it has decreased by -0.95% in the past 24 hours. Watch Cyclacel Pharmaceuticals stock price performance more closely on the chart.
What is Cyclacel Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Cyclacel Pharmaceuticals stocks are traded under the ticker CYCC.
Is Cyclacel Pharmaceuticals stock price growing?▼
CYCC stock has fallen by -3.91% compared to the previous week, the month change is a -14.96% fall, over the last year Cyclacel Pharmaceuticals has showed a -96.34% decrease.
What is Cyclacel Pharmaceuticals revenue for the last year?▼
Cyclacel Pharmaceuticals revenue for the last year amounts to 43,000 USD.
What is Cyclacel Pharmaceuticals net income for the last year?▼
CYCC net income for the last year is -11.21M USD.
Does Cyclacel Pharmaceuticals pay dividends?▼
Yes, CYCC dividends are paid en. The last dividend per share was 2.4 USD. As of today, Dividend Yield (FWD)% is 0%.
How many employees does Cyclacel Pharmaceuticals have?▼
As of May 20, 2026, the company has 12 employees.
In which sector is Cyclacel Pharmaceuticals located?▼
Cyclacel Pharmaceuticals operates in the Health & Wellness sector.
When did Cyclacel Pharmaceuticals complete a stock split?▼
The last stock split for Cyclacel Pharmaceuticals was on May 12, 2025 with a ratio of 1:16.
Where is Cyclacel Pharmaceuticals headquartered?▼
Cyclacel Pharmaceuticals is headquartered in Kuala Lumpur, United States.